mariane wrote:I often think about Tim. I hope he is doing well. His last scans were good. I keep my fingers crossed for him. Did somebody hear from him???
mariane wrote:Thank you so much Green Tea and Maia!
I meant Tim UK. I was so happy with his good scans after beginning the trial. It is one of trials may be the one to make change for us.
(...) I think it is time for the crc patients - right now. Maybe Tim's trial is the first one which will make the so much needed change for MSS crcs.
Stanfordmom wrote:That is great news, Maia!
Which trial is Tim UK on?
Thanks a lot,
Sha
Tim UK wrote:https://clinicaltrials.gov/ct2/show/NCT02650713
I moved onto Phase 1 trials a couple of months ago. I and my oncologist liked the science behind this one (above). It's a combination of bispecific antibody plus pd-l1 inhibitor. Previously I did 8 months on the (Phase 2/3) braf/MEK/egfr triplet which had amazing results until resistance occurred. I'm 7 weeks into this one and seeing good early results: several tumour sites have disappeared, sharp drop in SUV numbers in others, biopsies showing substantial necrosis. The docs seem excited. Side effects totally tolerable (nothing compared to the folfoxiri + avastin last summer, or even the triplet). Most importantly for me, I feel great ... totally unencumbered and kind of light / fresh / relaxed. I see they are recruiting at a few US sites.
Drug RO6958688 + PDL1
"Im"/"Tw" Im (Im = Immunotherapy; "Tw" = treading waters --it means a trial that it has chances of, at least, buy some time; it has some at least preclinical activity for CRC. The immuno ones are the ones aiming for complete responses/cure)
Locations (as of 12/2016)
California, Connecticut, Massachusetts, New York, North Carolina, France, Netherlands, Spain
NCT#
NCT02650713
NCT# Link
https://clinicaltrials.gov/ct2/show/NCT02650713
Comments (how it is supposed to work, the mechanism of action)
Membrane Bound CEA-CD3 Bifunctional + PDL1 combo
Allow prior PD-1? (it means if the trial accepts people who already did a trial with an anti PD-1 (which is and will be more and more common... going for an immuno trial after the other, instead of standard of care. In this case, yes, it allows previous PD-1, therefore the "OK"
PD1-OK
Publication?
http://clincancerres.aacrjournals.org/c ... 6.full.pdf
Publication #2?
http://www.tandfonline.com/doi/full/10. ... 16.1203498
Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”
Users browsing this forum: No registered users and 388 guests